Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Dr. Rachel Tate uptoTate
3 years 1 month ago
TMP-SMX PPX dispensed to less than a quarter of GPA pts at the time of RTX. Recent GC had the greatest association w/ PPX. Do you prescribe PPX for your GPA pts #Rheumtwitter? Abs 1071 #ACR22 @RheumNow https://t.co/qJyuGATtJo https://t.co/w4UaGgjEW1
Aurelie Najm AurelieRheumo
3 years 1 month ago
Shall we cycle TNFi in AxSpA?
CorEvitas registry 86 pts
70% TNFi monotherapy, 23% NSAIDs, 42% high & 24% v high DA
Cycling to 2nd line TNFi
At 6 months: very low achievement of ASDAS-LDA (15%), MCID in ASDAS (7%) & no MI.
https://t.co/S9vnz5PXuX
Abs#1499 #ACR22 @Rheumnow https://t.co/1IZIYcPCBz
Richard Conway RichardPAConway
3 years 1 month ago
Pan et al 11beta-hydroxysteroid dehydrogenase inhibitor SPI-62 mitigates glucocorticoid toxicity in mouse model. Human trial in PMR ongoing. @RheumNow #ACR22 Abstr#1549 https://t.co/t74Hazll9H https://t.co/4425RUwIz4
Dr. Rachel Tate uptoTate
3 years 1 month ago
Mepolizumab assoc'd w/ clinical benefits in EGPA, including in patients w/ and w/o a vasculitic phenotype. Abs 1074 #ACR22 @RheumNow https://t.co/VCGhGaci8b https://t.co/OV8A1vsx1G
Richard Conway RichardPAConway
3 years 1 month ago
Filho et al. Retrospective Brazilian study. ADA vs LEF in Takayasu arteritis. Comparable renission, relapses, steroid dose, ESR, CRP, imaging over median 15 weeks. More AEs in LEF but non-severe. @RheumNow #ACR22 Abstr#1553 https://t.co/499dUNmpUD https://t.co/AEk5cG7dc4
Richard Conway RichardPAConway
3 years 1 month ago
Juge @Juge_P_A @PhilippeDieude et al. RA-ILD patients have shorter telomere length than RA without ILD. RA-ILD similar telomere length to IPF. OR 0.54 for RA-ILD. Assoc with FVC%pred also. @RheumNow #ACR22 Abstr#1122 https://t.co/H5A7unpjjB https://t.co/IjvHmupykM
Richard Conway RichardPAConway
3 years 1 month ago
Del-Río-Guerrero et al. Sphygmomanometry-induced allodynia for fibromyalgia detection. 62% sensitivity and 84% specificity. Much pain = 23% sensitivity and 96% specificity. Only seems to apply in female patients. @RheumNow #ACR22 Abstr#1225 https://t.co/zCHfmvwOcn https://t.co/tjBBny0WSR
Akhil Sood MD AkhilSoodMD
3 years 1 month ago
Abstr 1255 Do Rheumatologists overcall sacroiliitis on imaging in axSpA?
Compared to central readers:
-Agreement w/ local readers = 87% agreement (X-Rays); 74.5% (MRIs)
- Agreement w/ Academic rheumatologists was greater vs community rheumatologists
#ACR22 @RheumNow https://t.co/j2vFoKA3n0
sheila RHEUMarampa
3 years 1 month ago
Study by Dr EPapachristodoulou on
features of #lupus pts w/ LAD: myo/pericarditis, cytopenias, nephritis,⬆️markers
Those w/LN biopsy: reactive(66.7%) vs. necrotizing(33.3%) pattern
👉Pts w/ necrotizing pattern: unexplained fevers, sicca& malar rash.
#ACR22 @RheumNow ABST1443 https://t.co/J4aMRnYk8N
Dr. Rachel Tate uptoTate
3 years 1 month ago
Avacopan's efficacy and safety profiles support use in AAV in Abs 1077 #ACR22 @RheumNow https://t.co/Zp05ofTgFP https://t.co/zA2sIEfYCS
Dr. John Cush RheumNow
3 years 1 month ago
Join us for our daily topic panels--we'll be live on Twitter, LinkedIn, FB and YouTube OR sign up directly below. #ACR22
https://t.co/Oql4iv6RyO https://t.co/S4t7ucliUF
While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with immunosuppressants and may not mount an adequate immune response to COVID vaccination. How does this therapy fare in RMD patients?
Dr. John Cush RheumNow
3 years 1 month ago
Much gusto for GUSTO: Efficacy of Tocilizumab Monotherapy for GCA
Dr. Richard Conway discusses abstract 0470 - being presented at the #ACR22 meeting.
https://t.co/btztbYWjq1 https://t.co/hrpZhIRLKO
Eric Dein ericdeinmd
3 years 1 month ago
Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE
Higher copays associated w/:
💊39% lower odds of HCQ adherence
💊56% lower AZA adherence
💊32% lower MMF adherence
Need better $$ and transparency into costs. Screen for determinants of health affecting affordability!
@Rheumnow https://t.co/1NdBb3GLzL
Poster Hall